New insights into membranous glomerulonephritis: From bench to bedside

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2428-2430

  Murtas, Corrado ^a   Ravani, Pietro ^b   Ghiggeri, Gian Marco ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALPHA ENOLASE; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C5B; IMMUNOGLOBULIN G4; MANGANESE SUPEROXIDE DISMUTASE; MEGALIN; MEMBRANE METALLOENDOPEPTIDASE; PHOSPHOLIPASE A2 RECEPTOR; RITUXIMAB;

ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE MODEL; HUMAN; IMMUNOFLUORESCENCE TEST; MEDICAL RESEARCH; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPECIES DIFFERENCE; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTIBODIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MALE; PROTEINURIA; RECEPTORS, PHOSPHOLIPASE A2;

EID: 79961087210     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr336     Document Type: Article

References (15)

1. Jones DB. Nephrotic glomerulonephritis. Am J Pathol 1957;33:313-329
2. Ponticelli C, Zucchelli P, Imbasciati E et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984;310:946-950 (Pubitemid 14173232)
3. Ruggenenti P, Cravedi P, Remuzzi G. Rituximab for membranous nephropathy and immune disease: less might be enough. Nat Clin Pract Nephrol 2009;5:76-77
4. Fervenza FC, Abraham RS, Erickson SB et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010;5:2188-2198
5. Kerjaschki D. Pathomechanisms and molecular basis of membranous glomerulopathy. Lancet 2004;364:1194-1196 (Pubitemid 39311326)
6. Debiec H, Guigonis V, Mougenot B et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002;346:2053-2060 (Pubitemid 34680597)
7. Debiec H, Nauta J, Coulet F et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004;364:1252-1259 (Pubitemid 39311346)
8. Beck LH Jr., Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21
9. Prunotto M, Carnevali ML, Candiano G et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010;21:507-519
10. Bruschi M, Carnevali ML, Murtas C et al. Direct characterization of target podocyte antigens and autoantibodies in human membranous glomerulonephritis: alpha-enolase and borderline antigens. J Prot 2011; doi:10.1016/j.jprot.2011.05.021 [epub ahead of print]
11. Murtas C, Bruschi M, Carnevali ML et al. In vivo characterization of renal auto-antigens involved in human auto-immune diseases: The case of membranous glomerulonephritis. Proteomics Clin Appl 2011;5:90-97
12. Hofstra JM, Beck LH Jr., Beck DM et al. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011;6:1286-1291
13. Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011;364:689-690
14. Hoxha E, Harendza S, Zahner G et al. An immunofluorescence test for Phospholipase-A2-Receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011;26:2526-2532
15. Beck LH, Fervenza FC, Beck DM et al. Anti-PLA2r autoantibodies and response to Rituximab treatment in membranous nephropathy. J Am Soc Nephrol 2011, in press